At the ECCO 2025 Congress, researchers presented a study showing that machine learning can identify gut microbial biomarkers that differentiate IBD patients—particularly those with Crohn’s disease—from healthy individuals. The study analyzed stool samples from over 3,700 participants, finding that supervised machine learning had the highest diagnostic accuracy (AUC 0.971).
Trending
- “Your gut is a universe” – Dr. Spiegel on the microbiome, AI, consciousness and the shrinking role of GIs sent
- What every physician should know before buying into a medical practice (KevinMD)
- The Affordable Care Act At Fifteen: Policy Surprises And Lessons (HealthAffairs)
- Cigna closes $3.7B sale of Medicare business to HCSC (Healthcare Dive)
- ASCOLT trial explores aspirin’s role in preventing colorectal cancer recurrence (News Medical)
- U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn’s disease (Johnson & Johnson)
- Private Equity in Health Care: Investment Trends, Challenges, and Future Implications (Knowledge at Wharton)
- Better Prep, Better Scope: Task Force Updates Colonoscopy Bowel Prep Advice (Medscape)